Description: The peptide is used to block Anti-TAF5L Antibody (#CPA5123) reactivity. Form: Lyophilized powder Gene Symbol: TAF5L Alternative Names: PAF65B; TAF5-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 5L; PCAF-associated factor 65 beta; PAF65-betaEntrez Gene (Human): 27097SwissProt (Human): O75529Purity : >85%Directions for Use : Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4°C for overnight or at room temperature for 2 hours.Quality Control : The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.Storage/Stability : Shipped at 4°C. Store at -20°C for one year.

• 
  Western blot analysis of TAF5L expression in Jurkat (A), HT29 (B), COS7 (C) whole cell lysates.
• 
  Immunohistochemical analysis of TAF5L staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugacompact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.